Effect of combination of valsartan and alprostadil on diabetic nephropathy: A meta-analysis

VernacularTitle:缬沙坦联合前列地尔治疗糖尿病肾病的meta分析
Author: Lili BIAN ; Wenbin SHANG
Publication Type:Journal Article
Keywords: Alprostadil; Valsartan; Diabetic nephropathy; Meta analysis
From: Chinese Journal of Endocrinology and Metabolism 2015;31(5):408-412
CountryChina
Language:Chinese
Abstract: The randomized controlled trials (RCTs) of treating diabetic nephropathy (DN) with alprostadil and valsartan were collected from CNKI,Wan fang date,VIP,PubMed,Embase,and Cochrane Library.The selected data was analyzed with RevMan 5.1 software.The effect of combination of valsartan and alprostadil in treating DN was evaluated.In 19 RCTs,675 cases were co-treated with alprostadil and valsartan and 670 were treated with valsartan.The results indicated that 24 h urine microalbumin excretion [WMD =-53.23,95％ CI (-67.55,-38.91),P＜0.01] and24 h urine protein[WMD=-0.38,95％ CI(-0.69,-0.07),P=0.02] in patients treated with combination of valsartan and alprostadil were reduced more markedly than in those treated with valsartan alone.There was no significant difference in blood urea nitrogen [WMD =-0.791,95 ％ CI (-20.62,4.79),P =0.22] and serum creatinine[WMD=-5.82,95％ CI(-19.22,7.58),P=0.39] between two kinds of treatment.These results suggest that combined treatment with valsartan and alprostadil shows advantageous effect on reducing urinary protein in DN.